TORONTO--(BUSINESS WIRE)-- Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that its Founder and Chief Executive Officer, Brendan Frey, Ph.D., F.R.S.C., will participate in a panel discussion during the Citi PCA – Private Company Digital Health Conference *VIRTUAL* on May 20, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210506005041/en/

Brendan Frey, Ph.D., F.R.S.C., Founder and CEO, Deep Genomics (Photo: Business Wire)

Details:

Session: Artificial Intelligence in Drug Discovery

Date and time: Thursday, May 20, 2021 from 1:30 – 2:00 p.m. EDT

About Deep Genomics

Deep Genomics is pioneering the application of artificial intelligence and machine learning to program the best RNA therapies for almost any gene in any genetic condition. The platform, called the AI Workbench, enables Deep Genomics to decode vast amounts of data on RNA biology, identify novel targets for genetically defined disease, and produce high quality therapeutic programs with a high rate of success. At some point in their life, everyone will face a genetic condition, and Deep Genomics aims to be there for them with a genetically precise therapy. Deep Genomics is located in Toronto, Canada and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on Twitter at @deepgenomics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005041/en/